These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26728154)

  • 1. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
    Yajima S; Shimizu H; Sakamaki H; Ikeda S; Ikegami N; Murayama JI
    BMC Health Serv Res; 2016 Jan; 16():2. PubMed ID: 26728154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.
    Takashima A; Ishiguro M; Sasaki K; Machida R; Nagashima F; Imaizumi J; Hamaguchi T; Yamamoto Y; Masuishi T; Asayama M; Ueno H; Shinozaki K; Kudo T; Machida N; Matsuoka H; Ishida H; Yamaguchi T; Nogami H; Yamada T; Takegawa N; Kito Y; Tonoike Y; Sawada R; Tsukamoto S; Kanemitsu Y;
    Jpn J Clin Oncol; 2024 Oct; 54(10):1107-1114. PubMed ID: 39210583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
    Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
    Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
    Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
    Pettersson K; Carlsson G; Holmberg C; Sporrong SK
    Acta Oncol; 2012 Sep; 51(7):840-8. PubMed ID: 22937953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
    Parikh RC; Du XL; Robert MO; Lairson DR
    J Manag Care Spec Pharm; 2017 Jan; 23(1):64-73. PubMed ID: 28025930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
    Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM
    BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis].
    Shida T; Endo Y; Shiraishi T; Yoshioka T; Suzuki K; Kobayashi Y; Ono Y; Ito T; Inoue T
    Yakugaku Zasshi; 2018; 138(1):83-90. PubMed ID: 29311468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
    Levy-Piedbois C; Durand-Zaleski I; Juhel H; Schmitt C; Bellanger A; Piedbois P
    Ann Oncol; 2000 Feb; 11(2):157-61. PubMed ID: 10761749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
    Iveson TJ; Hickish T; Schmitt C; Van Cutsem E
    Eur J Cancer; 1999 Dec; 35(13):1796-804. PubMed ID: 10673994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
    Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
    Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
    Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG; Habbema JD; Kuipers EJ
    J Natl Cancer Inst; 2009 Oct; 101(20):1412-22. PubMed ID: 19779203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group.
    Nishina T; Boku N; Kurokawa Y; Sasaki K; Machida R; Yoshikawa T
    Jpn J Clin Oncol; 2024 Oct; 54(10):1100-1106. PubMed ID: 39180720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
    Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
    Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in the cost of medications for the treatment of colorectal cancer.
    Ferro SA; Myer BS; Wolff DA; Poniewierski MS; Culakova E; Cosler LE; Scarpace SL; Khorana AA; Lyman GH
    Am J Manag Care; 2008 Nov; 14(11):717-25. PubMed ID: 18999906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
    Lacas B; Bouché O; Etienne PL; Gasmi M; Texereau P; Gargot D; Lombard-Bohas C; Azzedine A; Denis B; Geoffroy P; Auby D; Michel P; Pignon JP; Lepage C; Ducreux M; Borget I
    Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):601-608. PubMed ID: 30739558
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
    Ruiz-Millo O; Albert-Mari A; Sendra-Garcia A; Jimenez-Torres NV
    J Oncol Pharm Pract; 2014 Oct; 20(5):341-50. PubMed ID: 24177355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.